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The value of Ultrasound Monitoring 
of Adnexal Masses for early 
Detection of Ovarian Cancer
Elizabeth Suh-Burgmann* and Walter Kinney
Division of Gynecologic Oncology, The Permanente Medical Group, Walnut Creek, CA, USA
Although ultrasound has so far been found to be ineffective as a screening tool for 
ovarian cancer, it is commonly used as a means of evaluating or following ovarian or 
adnexal masses once they are detected. We review the use of serial ultrasound for the 
management of adnexal masses and propose an approach to monitoring based on an 
understanding of the overall risk of cancer among the population in question and an 
assessment of how the potential benefit of monitoring compares with potential risk. In 
our approach, masses that are symptomatic, large (>10 cm), associated with an elevated 
CA 125 level or overt signs of malignancy, or that are determined to have a worrisome 
appearance by stringent ultrasound criteria should be evaluated surgically. Women with 
masses that have none of these characteristics should be offered monitoring. Short-
term initial ultrasound monitoring carries significant potential benefit in terms of aiding 
detection of early malignancy and avoidance of unnecessary surgery. However, if a mass 
remains stable but persistent, the potential benefit of ongoing monitoring wanes with 
time, whereas the potential harms, in terms of patient anxiety, cost, and the risk of 
incidental findings and unnecessary surgery increase. Therefore, monitoring of stable 
lesions should be limited in duration in order to limit potential harms from overtreatment 
and overdiagnosis.
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inTRODUCTiOn
Although the majority of women with epithelial ovarian cancer present with late stage disease, 
approximately 15% have early stage disease at diagnosis (1). Many early stage cases present with 
a large mass or worrisome clinical signs, but for a small subset, the initial presentation is a small, 
asymptomatic adnexal mass with no other factors that would raise suspicion of cancer. Biopsy of 
adnexal masses is generally not recommended since ovarian cancer is known to spread by direct 
peritoneal extension, and therefore, if a mass is malignant, biopsy could theoretically worsen prog-
nosis. As a result, concern that a mass in an older woman may represent an early cancer leads many 
women with small masses to undergo unnecessary surgery with accompanying morbidity, despite 
the fact that the overwhelming majority of these masses are found to be benign.
The alternative to immediate surgery for masses of uncertain nature is ultrasound monitoring. 
Here, we discuss when monitoring of masses in postmenopausal women should be considered, the 
distinction between initial short-term ultrasound monitoring and prolonged monitoring in terms of 
potential value, as well as potential harms. Based on these considerations, we propose an approach 
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to ultrasound monitoring for adnexal masses based on published 
clinical data that aims to maximize benefit and minimize harm.
wHen SHOULD MOniTORinG Be 
COnSiDeReD?
Surgery is appropriate for symptomatic masses and masses that 
are associated with other signs of malignancy, such as elevated 
CA125 (in postmenopause), ascites, or evidence of metastatic 
disease, or in women at high genetic risk for ovarian cancer. 
Surgery is also appropriate for large masses (>10  cm), which 
are less likely to regress, have a higher risk of symptoms, and are 
often more difficult to characterize on ultrasound. Therefore, the 
women for whom ultrasound monitoring is an option are women 
whose presentation does not include any of these characteristics: 
average risk women with smaller, asymptomatic masses.
wHAT iS THe RiSK OF CAnCeR?
Appropriate management of women with smaller asymptomatic 
masses should be based on the risk of cancer – the lower the risk 
of cancer is for a group, the lower the rate of surgery should be. 
Unfortunately, there is little “real world” data on what the risk 
of cancer is among women who are potential candidates for 
monitoring. The traditional teaching within gynecology has been 
that complex adnexal masses in older women are cancer until 
proven otherwise. However, this view was not based on the subset 
of women with characteristics that would make them candidates 
for observation, and it was often drawn from referral populations 
where the prevalence of cancer is elevated (2–5). Furthermore, 
this impression of risk was established during an era when most 
masses came to the attention of patients and providers due to 
symptoms or being palpable on exam. It is clear that with ris-
ing rates of utilization of imaging of all types, including office 
ultrasound, adnexal masses are increasingly found incidentally 
in studies obtained for an entirely separate concern (6–8). Trial 
data demonstrate that among older women who have an adnexal 
mass identified through ultrasound screening, the overall risk of 
invasive cancer is approximately 1–2% (9–11). In the UKCTOCS 
trial, an ongoing randomized controlled screening trial of over 
20,000 postmenopausal women in the United Kingdom, of 
48,230 women who had an initial ultrasound screen, 9.1% had 
an abnormal scan, and among these women, the absolute risk of 
epithelial ovarian cancer over the following 3 years was 1.08% (9). 
Although the risk of cancer for women identified by screening is 
expected to be lower than the risk for women found to have a mass 
in clinical practice, the degree to which they differ will depend on 
the proportion of women in clinical practice who are diagnosed 
with a mass as the result of signs or symptoms related to ovarian 
malignancy. One in every three physicians reportedly engage in 
ovarian cancer screening of low-risk women despite evidence to 
date that ovarian cancer screening using transvaginal ultrasound 
and CA125 tumor marker testing is ineffective at reducing ovar-
ian cancer mortality (12). In addition to inappropriate screening, 
the widespread use of ultrasound effectively results in inadvertent 
screening. Unlike mammography, which is rarely used for any 
indication other than screening, pelvic ultrasound is used for a 
range of clinical indications, such as checking IUD placement 
or evaluating fibroids. If the UKCTOCS experience holds, each 
ultrasound exam on a postmenopausal woman has a 9% chance 
of incidentally finding an adnexal mass. Although large masses or 
masses associated with ascites are usually diagnosed as a result of 
symptoms, the women who are candidates for ultrasound moni-
toring are women with small isolated asymptomatic masses. For 
these reasons, the difference in the risk of malignancy observed 
for women identified by screening compared to women who 
undergo monitoring may not be as great as expected. We evalu-
ated the risk among women who were found to have small masses 
in the course of routine care by identifying a population-based 
cohort of 1363 women over age 50 with complex masses <6 cm in 
size not associated with other evidence of cancer (13). A total of 7 
cancers and 11 borderline tumors were found with 24 months of 
follow-up. The majority (994/1363, 73%) underwent ultrasound 
monitoring, with 5 of the cancers and 7 of the borderline tumors 
found in the monitored group during follow-up for an overall risk 
of 1.3%, and 0.5% for invasive cancer specifically.
TRiAGe TO SURGeRY veRSUS 
OBSeRvATiOn
Several strategies have been proposed to better identify masses that 
are likely to be malignant. Although elevated CA125 levels raise 
the likelihood of cancer, a normal value is seen in approximately 
50% of early stage cases (14), and therefore, does not exclude pos-
sible cancer. Whether longitudinal measurement of CA125 over 
time, evaluated by the risk of ovarian cancer algorithm (ROCA), 
will be effective as a screening method for low-risk women is 
a question currently being studied within the multimodality 
screening arm of UKCTOCS (15). A number of algorithms that 
combine clinical and ultrasound criteria have been proposed. The 
risk of malignancy index (RMI) is a score generated by assess-
ment of ultrasound features, menopausal status, and the serum 
CA125 level (international unit per milliliter). The ultrasound 
features in RMI are multilocularity, solid areas, and bilaterality 
(16). The International Ovarian Tumor Analysis (IOTA) group 
developed two logistic regression models (LR1 and LR2), which 
rely more heavily on ultrasound features and also include age, 
personal history of ovarian cancer, and tenderness of the mass on 
physical exam (LR1) to predict malignancy (17). The ultrasound 
findings that lead to a higher score are ascites, blood flow in papil-
lary projections, solid nature of the tumor, maximum diameter of 
the largest solid component, irregular internal cyst wall, lack of 
acoustic shadows, and higher degrees of vascular flow. The group 
also developed and evaluated a set of “simple rules (SR)” that 
produce a score based solely on the presence or absence of benign 
or malignant ultrasound features, in which malignant features are 
defined as irregular solid tumor, ascites, at least four papillary 
projections, irregular multilocular solid tumor at least 10 cm, and 
very strong intratumoral blood flow (18). Recently, they reported 
an analysis of their studies in which they found that all IOTA 
strategies (LR1, LR2, SR, and combinations of the above) were 
superior to RMI for predicting malignancy among masses with 
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sensitivities in the range of 90–96% and specificity of 74–79% 
(19). Interestingly, they found LR1 was only slightly more sensi-
tive but significantly less specific than “subjective assessment” 
alone which relied entirely on expert radiology impression (93.7, 
77.6 versus 92.5, 87.7, respectively). However, the generalizability 
of these findings is debatable due to a higher prevalence of cancer 
in the populations studied as well as a level of radiology expertise 
that may not be reproducible in other settings (20). Finally, inves-
tigators from the Kentucky ovarian screening study developed a 
“morphology index” (MI) based on mass volume and proportion 
of solid component, and found that in their study, 85% of cancers 
and borderline tumors had a score of at least 5 at the time that the 
decision was made for surgery (21). Although debate continues 
regarding the superiority as well as generalizability of one strategy 
compared to another, from a practical standpoint, clinical crite-
ria, such as personal history of ovarian cancer, elevated CA125, 
and evidence of ascites or metastases, as well as large mass size 
>10  cm, are already generally considered sufficient reason to 
direct a woman with a mass to immediate surgical evaluation. 
Therefore, further triage of women without these characteristics 
to either ultrasound observation versus surgery relies mainly on 
ultrasound characteristics. Among the ultrasound features that 
are associated with malignancy, the presence of large solid areas is 
the most consistent characteristic included in ultrasound-based 
prediction strategies. The significance of solid areas has also been 
demonstrated in screening trials. In UKCTOCS, masses without 
solid elements had an absolute risk of 0.4%, whereas masses with 
solid elements had an absolute risk of 4.45% (9). Analysis of the 
ultrasound abnormalities seen in PLCO also found that both 
the size of the mass and the presence of solid components cor-
related with risk of malignancy, with all masses <5 cm and larger 
masses without solid areas being low risk (22). Requiring solid 
components to demonstrate vascular flow by Doppler has been 
shown to increase the specificity of morphology for malignancy 
(23–26). Given the overall low risk of malignancy among women 
who are candidates for monitoring, the ultrasound criteria used 
to exclude women from initial short-term monitoring should be 
highly specific, in order to avoid exposing women to excessive 
unnecessary surgery. In our practice, we support excluding only 
masses that demonstrate significant solid vascular components 
from consideration of initial monitoring.
SCHeDULe OF MOniTORinG
When considering ultrasound monitoring, a distinction must 
be made between initial, short-term repeat exam, limited 
monitoring for up to 1–2  years and indefinite, potentially life-
long monitoring of stable masses. Initially, monitoring serves to 
identify masses with aggressive growth patterns, and it helps to 
avoid surgery on masses that are benign or transient in nature 
such as hemorrhagic cysts. The Society of Radiologists in 
Ultrasound published guidelines in 2010, based on committee 
consensus opinion, which recommended a follow-up interval of 
“6–12  weeks” for indeterminate masses among premenopausal 
or perimenopausal women, but immediate surgical considera-
tion for postmenopausal women (27). However, there is growing 
consensus that a repeat exam in 6–8 weeks is safe and does not 
negatively impact stage at diagnosis (28–30). In the Kentucky 
ovarian cancer screening study which used serial transvaginal 
ultrasound as well as CA125, it was found that over 75% of cystic 
and solid lesions resolved on monitoring over 12 months (28). 
The investigators credit the use of serial ultrasound in decreasing 
the rate of false positive results and did not find that initial moni-
toring resulted in more advanced stage at diagnosis. A similar 
strategy is used in the ultrasound only arm of the UKCTOCS 
trial in which women with initial ultrasound abnormalities are 
directed to undergo a repeat ultrasound 6–8 weeks later that is 
performed by a more experienced ultrasonographer (30). Only 
if the mass is persistent at that time is a clinical assessment 
made regarding the suspicion for cancer. Indeterminate masses 
that are stable on the initial 6- to 8-week exam can be further 
monitored. The American College of Obstetrics and Gynecology 
(ACOG) Practice Bulletin on Management of Adnexal Masses 
states “Repeat imaging is recommended if there is uncertainty 
regarding a diagnosis …. The frequency of repeat imaging has not 
been determined” (31). Although the optimal interval between 
follow-up studies for stable masses has not been rigorously 
studied, reimaging stable masses at 3-month intervals has been 
adopted by many as a reasonable schedule (26, 28, 29, 32). In our 
study of postmenopausal women with small complex masses, all 
five cancers diagnosed during follow-up demonstrated growth 
on the first repeat ultrasound, done 2–7 months later (13). All 
patients who had reimaging done within 6 months were found 
to have stage I disease at surgery. These results support the view 
that 3-month intervals between exams provide an opportunity to 
detect worrisome growth while still supporting early detection. 
If progression of the mass is seen on repeat imaging, surgical 
removal is appropriate. In our experience, women also elect 
eventual surgery due to cumulative anxiety or because a follow-
up ultrasound raises concerns for progression even though the 
mass is unchanged, due to variability in ultrasound technique and 
reporting styles. Therefore, if monitoring is to be effective, follow-
up studies should state explicitly whether any changes observed 
are potentially due to variation in image acquisition, in order to 
differentiate masses that are equivocably changed from those that 
are definitely changed.
DURATiOn OF MOniTORinG FOR STABLe 
MASSeS
The question of how long monitoring should be continued for 
stable but persistent masses is best viewed from the standpoint 
of potential benefit versus potential risk. Since the only potential 
benefit of monitoring asymptomatic masses is to identify masses 
that are malignant by observing growth over time, the longer a 
mass is observed to be stable, the less likely it is to represent a 
malignancy, and therefore the lower the potential benefit of fur-
ther monitoring. Within the population-based cohort we stud-
ied, all five epithelial cancers as well as nine borderline tumors 
demonstrated clear growth on their first follow-up ultrasound 
(13). Similarly, in the Kentucky study, all malignant tumors were 
identified as worrisome within a relatively short time frame from 
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initial detection, with malignant tumors receiving only 2.1 scans 
over a mean 2.3 months prior to removal (21). The recognition 
that ovarian cancers are heterogeneous in behavior with some 
tumors having more indolent growth patterns than others has 
led to a new paradigm that categorizes ovarian cancers as Type 
1 or Type 2 based on their purported pathogenesis (33, 34). 
Type 2 cancers, which include high grade serous histology and 
represent the majority of ovarian epithelial malignancies, are 
thought to arise primarily from fallopian tube rather than ovarian 
precursors, which helps explain the failure of screening trials to 
detect these cancers at early stage. Type 1 cancers, which include 
low grade endometrioid, clear cell, and mucinous histologies, 
are thought to arise from endometriosis or ovarian precursors 
and generally demonstrate a more indolent growth pattern. 
Therefore, the paradigm raises the question of whether screen-
ing, or indefinitely prolonged monitoring of stable masses, which 
eventually becomes tantamount to screening, confers significant 
benefit for early detection of Type 1 cancers. This is an open 
question. However, any prediction of benefit from detection of 
Type 1 cancers must take into consideration the fact that benefit is 
realized only if the stage at diagnosis is earlier than would other-
wise occur. Since this subset of cancers come to clinical attention 
much more often at early stage (35), such benefit is less likely. In 
our study, three of the seven cancers were Type 1 and all demon-
strated growth on follow-up ultrasound within 7 months with no 
additional cancer diagnoses within 24 months of follow-up (13). 
Similarly, in UKCTOCS, all of the Type 1 cancers found among 
women who demonstrated an abnormality on initial ultrasound 
evaluation were diagnosed within the first year of follow-up (9). 
No measurable benefit from monitoring of stable masses beyond 
2 years has ever been demonstrated.
POTenTiAL HARMS OF MOniTORinG
Although the potential benefit of monitoring wanes over time, 
the potential harms are cumulative. The most significant harm 
occurs from unnecessary surgery for a benign asymptomatic 
mass. Benign adnexal masses are known to be extremely com-
mon. Depending on the size threshold of what constitutes a 
“mass,” autopsy studies have shown that between 17 and 56% of 
postmenopausal women who died from non-gynecologic causes 
harbor ovarian cystic or solid masses at the time of death (36, 37). 
Although surgical removal is appropriate for symptomatic masses, 
there is no clear benefit of removal of a benign asymptomatic 
adnexal mass. Thus, surgery that is done for an asymptomatic 
mass that does not reveal cancer is appropriately considered as 
a harm in cancer screening trials. Although minimally invasive 
techniques have lowered overall morbidity of surgery, such 
procedures were still found to be associated with an average 6% 
serious complication rate across screening trials (11). If bilateral 
salpingo-oophorectomy is done, depending on patient age, there 
is also potential harm from loss of hormone function, as negative 
impacts on cardiovascular health, bone health, and possibly cog-
nitive function have been reported in women whose ovaries were 
removed prior to 50 years of age (38). Costs to the health-care 
system from surgery and complications as well as both direct and 
indirect costs to patients are substantial. Although initial moni-
toring helps to avoid immediate surgery, prolonged monitoring 
of stable masses increases the likelihood of unnecessary surgery 
for incidental findings. It is not uncommon for a woman who is 
being followed for a stable adnexal abnormality to be found on 
repeat imaging to have a new adnexal abnormality, given the high 
prevalence of adnexal lesions, which then triggers another round 
of evaluation with either surgery or observation.
COnCLUSiOn
In summary, ultrasound monitoring of adnexal masses is valuable 
in identifying early cancers among women who have small masses 
are asymptomatic and do not demonstrate other signs of cancer 
such as elevated CA125 or ascites. However, the overall risk of 
cancer for these women is very low. A short-term repeat ultra-
sound at 6–8 weeks to evaluate for either regression or growth 
helps to avoids surgery on transient masses and does not appear 
to worsen prognosis in the event that the mass represents an early 
cancer. In this population, the ultrasound criteria used to label 
adnexal masses as “highly worrisome,” and therefore excluded 
from consideration of any monitoring, should be clearly defined 
and relatively stringent, given the overall low risk of malignancy. 
The presence of significant solid components that demonstrate 
vascular flow appears to be the ultrasound characteristic for which 
there is the greatest consensus as to its specificity for malignancy. 
Masses demonstrating clear progression during monitoring 
should be removed. For stable masses, repeat ultrasound at 
3-month intervals, to observe for worrisome growth or changes 
in complexity is appropriate. However, since the potential benefit 
in terms of cancer identification wanes with time, the duration of 
monitoring of stable masses should be limited to 1–2 years in order 
to limit potential harms from overtreatment and overdiagnosis.
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